Johnson & Johnson Declares Crucell Offer Unconditional

U.S. pharmaceuticals company Johnson & Johnson (JNJ) said Tuesday it completed the tender offer for Dutch biotechnology company Crucell NV (CRXL.AE) and has declared the offer unconditional.

MAIN FACTS:

- Johnson & Johnson declares the Offer for unconditional

- As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.

- Share Acceptance Level is 95.24% of the issued and outstanding share capital of Crucell

- Settlement of the Offer will take place on 25 February 2011

- Remaining Shares can be tendered in a Subsequent Offering Period ending 8 March 2011

- Johnson & Johnson intends to acquire the remaining Shares not tendered by means of buy-out proceedings in accordance with article 2:92a and/or 359c of the Dutch Civil Code, to be initiated as soon as reasonably practicable under applicable rules and regulations

- By Amsterdam Bureau, Dow Jones Newswires; amsterdam@dowjones.com

Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024